HDAC9 and liver cancer: Small molecular drugs targeting epigenetic facets attracted rising attention in liver cancer treatment, including HDAC inhibitors Belinostat and Panobinostat and DNMT inhibitor azacytidine.25, 26, 27, 28, 29